Company Overview
More
Shanghai Fuhong Hanlin Biotechnology Co., Ltd. is a Chinese company mainly engaged in the research, development, production and sales of monoclonal antibody products. The company's main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) bioanalogue HLX02, trimethoprim (adamumab) bioanalogue HLX03 and Avetine (bevacizumab) bioanalogue HLX04, as well as candidate biological innovation drugs. It includes HLX06 (a new type of VEGFR2 inhibitor), HLX07 (a kind of EGFR inhibitor), HLX10 (a new type of PD-1 inhibitor), HLX20 (a new type of PD-L1 inhibitor) and HLX22 (a new type of HER2 inhibitor). The company also provides related technical services. The company mainly operates in China and the United States.
CEO： Wenjie Zhang
Market： Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
02696 HENLIUS-B
16.920+1.040+6.55%
YOY
Do not show
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Assets
Current assets
Inventory
37.64%
420.11M
110.14%
346.74M
135.02%
305.22M
144.84%
165M
Accounts receivable
50.72%
295.74M
152.06%
216.41M
557.77%
196.21M
388.51%
85.86M
Advance deposits and other receivables
-23.88%
223.97M
-25.58%
197.12M
49.86%
294.25M
68.53%
264.88M
Cash and equivalents
-36.52%
707.33M
7.46%
1.23B
-51.57%
1.11B
225.54%
1.15B
Secured deposit
--
--
--
--
--
--
41.52%
9.35M
Total current assets
-13.76%
1.65B
19.19%
1.99B
-28.21%
1.91B
175.66%
1.67B
Non-current assets
Property, plant and equipment
24.77%
1.23B
73.26%
1.12B
96.7%
984.91M
67.77%
647.09M
Intangible assets
23.53%
3.63B
27.72%
3.2B
35.28%
2.94B
48.47%
2.5B
Other illiquid assets
49.57%
223.67M
-38.43%
159.34M
-27.61%
149.54M
-33.02%
258.81M
Special items of non-current assets
-3.11%
438.2M
1.07%
460.35M
26.8%
452.28M
188.8%
455.48M
Total non-current assets
22%
5.53B
27.77%
4.94B
39.83%
4.53B
47.74%
3.86B
Total assets
11.39%
7.17B
25.18%
6.93B
9.14%
6.44B
71.81%
5.54B
Liabilities
Current liabilities
Accounts payable
28.27%
383.47M
-15.82%
186.13M
24.48%
298.95M
70.52%
221.11M
Other payables and accrued expenses
97.18%
867.28M
48.18%
406.89M
7.49%
439.85M
-4.36%
274.6M
Bank loans and overdrafts
32.16%
1.57B
289.14%
1.63B
327.14%
1.19B
35.89%
418.23M
Investment contract liabilities - current liabilities
--
--
--
57.18M
--
--
--
--
Special items of current liabilities
164.82%
138.3M
--
--
63%
52.23M
245.24%
32.29M
Total current liabilities
49.52%
2.96B
140.71%
2.28B
106.28%
1.98B
28.93%
946.23M
Net current assets
-1788.2%
-1.31B
-139.36%
-285.44M
-104.09%
-69.51M
668.78%
725.28M
Total assets less current liabilities
-5.53%
4.21B
1.36%
4.65B
-9.73%
4.46B
84.46%
4.59B
Non-current liabilities
Long-term bank loan
63.11%
1.05B
265.91%
977.28M
94.82%
645.13M
-47.07%
267.08M
Long-term accounts payable
--
54.43M
--
--
--
--
--
--
Deferred income-non-current liabilities
64.12%
155.74M
168.29%
148.01M
162.85%
94.9M
48.26%
55.17M
Investment contract liabilities-non-current liabilities
--
--
--
656.31M
--
--
--
--
Special items of non-current liabilities
25.55%
653.93M
--
--
-9.02%
520.87M
40.08%
559.52M
Total non-current liabilities
51.98%
1.92B
102.05%
1.78B
34.17%
1.26B
-6.32%
881.78M
Total liabilities
50.48%
4.88B
122.06%
4.06B
70.6%
3.24B
9.13%
1.83B
Total assets less total liabilities
-28.2%
2.3B
-22.58%
2.87B
-20.04%
3.2B
139.7%
3.71B
Total equity and non-current liabilities
-5.53%
4.21B
1.36%
4.65B
-9.73%
4.46B
84.46%
4.59B
Equity
Share capital
0%
543.5M
0%
543.5M
0%
543.5M
14.56%
543.5M
Reserve
-33.97%
1.75B
-26.46%
2.33B
-23.19%
2.66B
195.05%
3.16B
Legal reserve
-33.97%
1.75B
-26.46%
2.33B
-23.19%
2.66B
195.05%
3.16B
Shareholders' Equity
-28.2%
2.3B
-22.58%
2.87B
-20.04%
3.2B
139.7%
3.71B
Total equity
-28.2%
2.3B
-22.58%
2.87B
-20.04%
3.2B
139.7%
3.71B
Total equity and total liabilities
11.39%
7.17B
25.18%
6.93B
9.14%
6.44B
71.81%
5.54B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
Unqualified Opinion--Unqualified Opinion--
Auditor
Ernst & Young accounting firm--Ernst & Young accounting firm--
Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.
The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%